Dr. Giorgio Roscigno
Dr. Roscigno is a senior public health specialist with broad pharma and diagnostics l experience in the private as well as the public sector.
He has 18 years experience in a Research based MNC ( Aventis Sanofi) and 13 years experience in the Public Private Mix having contributed to the creation and lead of 3 major Product Development Partnership: The Global Alliance ( CEO 2000 -2003) FIND ( CEO 2003-2011) and The African Society for Laboratory Medicine (COO 2012-2013).
Dr. Roscigno is currently since 2013 leading a New organization called NEXT2PEOPLE (Geneva, Pretoria): a paradigm shift with a great focus on exploring innovative roles for the private sector in Public Health for Emerging Economies.
As founder and first Chief Executive Officer at FIND ( Geneva) in 2003, has overseen the development of 5 new WHO-approved diagnostic tools for Tuberculosis, the distribution and implementation of these tools in 27 High Burden Countries ( among these the Genexpert broadly considered the first revolutionary tool in TB Diagnosis). He was also among the founding members and first CEO of the Global Alliance for TB Drug Development ( New York /Brussels), a non-profit public-private partnership dedicated to TB drug discovery.
Roscigno spent 18 years in a research based Pharmaceutical Company. He has served as Medical Director for Africa, Asia, and Europe (Merrel Dow), the European Clinical Research Director for Anti-infectives ( Marion Merrel Dow); and finally the International Medical Director for Anti-infectives with Aventis in Paris, France.
Roscigno has contributed significantly, inspired and led the clinical work of all TB fixed-dose combinations containing rifampicin, the development of rifapentine ( TB) and DFMO eflornithine ( sleeping sickness) up to their FDA approvals.